Serum Levels of Osteoprotegerin in Patients with Acne Vulgaris

Authors
Ahmed A. W. Saleh¹, Rehab M. Salem¹, Asmaa A. El-Fallah², Haider S. Abdullah³*

Dermatology and Andrology¹, Clinical and Chemical Pathology² Departments, Faculty of Medicine, Benha University, Egypt, M.B.B.Ch.(Al-Mustansiriya University-Iraq)³

*Corresponding Author
Haider Sameer Abdullah

Abstract

Background: Acne vulgaris (AV) is a common chronic inflammatory skin disease involving pilosebaceous follicles characterized by comedones, papules, pustules, nodules, and sometimes scars.

Aim of the Work: The aim of this study is to evaluate the serum levels of osteoprotegerin in patients with acne vulgaris and assess its relation to the severity of the disease.

Methods: This case-control study was conducted in the outpatient Clinic of Dermatology and Andrology, Department of Benha University. The study included 80 participants; 60 patients suffering from acne vulgaris, in addition to 20 apparently healthy, age and sex matched individuals as a control group. Determination of serum level of osteoprotegerin was done by ELISA technique.

Results: The mean serum level of OPG in patients group (124.390±5.741) was significantly higher than that in the control group (47.394±29.332) as p<0.001. At a Cutoff point >48.4, Serum OPG had 95% Sensitivity and 70% Specificity and 88.9% accuracy to differentiate between Patients and Controls.

Conclusion: Osteoprotegerin may play a role in acne pathogenesis.

Keywords: Acne vulgaris, osteoprotegerin, case-control.

Introduction

Acne vulgaris (AV) is a common chronic inflammatory skin disease involving pilosebaceous follicles characterized by comedones, papules, pustules, nodules, and sometimes scars[1]. Acne can present as noninflammatory lesions, inflammatory lesions, or a mixture of both, affecting mostly the face but also the back and the chest[2]. The disease commonly begins in adolescence and is perceived as teenage disease; however, it often persists into adulthood[3].

Osteoprotegerin (OPG), also known as Osteoclastogenesis inhibitory factor (OCIF), or tumor necrosis factor receptor super family member 11B (TNFRSF11B), is a protein that in humans is encoded by the TNFRSF11B gene. Osteoprotegerin is a cytokine receptor, and a member of the tumor necrosis factor (TNF) receptor super family[4]. Osteoprotegerin is a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL). By binding RANKL, OPG prevents RANK-mediated nuclear factor kappa B (NF-kB) activation which is a central and rapid acting transcription factor for immune-related genes, and a key regulator of inflammation, innate immunity, and cell survival and differentiation[5]. Osteoprotegerin is produced...
by a variety of tissues including the cardiovascular system (heart, arteries, veins), lung, kidney, intestine, and bone, as well as hematopoietic and immune cells. The expression and production of the protein is modulated by various cytokines, peptides, hormones and drugs. Cytokines, including TNF-α, interleukin (IL1)-1α, IL1-18, transforming growth factor (TGF)-β, bone morphogenetic proteins, and steroid hormones such as 17 β-estradiol are known to up-regulate OPG mRNA levels. RANKL may promote peripheral immune tolerance. For instance, it has been reported that RANKL-expressing keratinocytes in inflated skin trigger epidermal dendritic cells to induce a Treg phenotype in infiltrating T cells.

The aim of this study was to evaluate the serum levels of osteoprotegerin in patients with acne vulgaris and assess its relation to the severity of the disease.

Subjects and Methods

I. Subjects: This case-control study was conducted in Outpatient Clinic of Dermatology and Andrology Department of Benha University. The study included 80 participants; 60 patients suffering from acne vulgaris, in addition to 20 apparently healthy, age and sex matched individuals as control group. Written informed consents were obtained from all participants. The study was approved by the local Ethics Committee on Research involving human subjects of Benha Faculty of Medicine.

II. Methods

Patients under study were subjected to full history taking, general examination including BMI and dermatological clinical examination to detect acne lesions and to determine their types, distribution and grading. The grading of acne lesions was assessed according to the global acne grading system (GAGS). Laboratory investigation: Determination of serum level of osteoprotegerin was done by ELISA technique.

Blood Sampling

Five mls of venous blood sample were collected from each participant after overnight fasting under complete aseptic condition. Collected sample was put on plain plastic tube and allowed to clot, then centrifuged at 3000 r.p.m for 10 min. The separated serum was stored in aliquot at -20 °C for subsequent determination of osteoprotegerin using ELISA technique.

Determination of serum level of osteoprotegerin: Serum level of osteoprotegerin was done by ELISA kits supplied by Shanghai Sun red Biological Technology company, Shanghai, China.

Test Principle: The microtiter plate provided in this kit has been pre-coated with an antibody specific to osteoprotegerin. Standards and samples were added to the appropriate microtiter plate wells with a biotin-conjugated polyclonal antibody preparation specific for osteoprotegerin and Avidin conjugated to Horseradish Peroxidase (HRP) was added to each micro plate well and incubated. Then a TMB substrate solution was added to each well. Only those wells that contain, biotin-conjugated antibody and enzyme-conjugated Avidin was exhibited a change in color. The enzyme-substrate reaction was terminated by the addition of a sulphuric acid solution and the color change was measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of in the samples was then determined by comparing the O.D. of the samples to the standard curve.

Assay Procedure: All reagents were allowed to reach room temperature. All the reagents were
mixed thoroughly by gently swirling before pipetting.

1. 100 μl of Standard, Blank, or Sample per well were added. It was covered with the Plate sealer then incubated for 2 hours at 37°C.

2. The liquid of each well was removed. 100 μl of Detection Reagent A working solution were added to each well. It was covered with the Plate sealer then incubated for 1 hour at 37°C. Detection Reagent A working solution appeared cloudy. It was Warmed to room temperature and mixed gently until solution was appeared uniform.

3. Each well was aspirated and washed, the process was repeated three times for a total of three washes. Each well was washed by filling with Wash Buffer (approximately 400 μl) using a squirt bottle, multi-channel pipette, manifold dispenser or auto washer. After the last wash, all the remaining Wash Buffer were removed by aspirating or decanting. The plate was inverted and blotted it against clean paper towels.

4. 100 μl of Detection Reagent B working solution were added to each well. It was covered with a new Plate sealer then incubated for 1 hour at 37°C.

5. The aspiration/wash was repeated as in step 4.

6. 90 μl of Substrate Solution were added to each well. It was covered with a new Plate sealer then incubated within 15-30 minutes at 37°C and Protected from light.

7. 50 μl of Stop solution were added to each well. If color change does not appear uniform, gently tap the plate to ensure thorough mixing.

8. The optical density of each well was determined at once, using a microplate reader set to 450 nm.

Results

✓ This study included 80 participants, 60 acne patients and 20 subjects control. There was insignificant difference between patients and controls regarding age, BMI and sex (p=0.515, 0.386 and 0.242 respectively) (Table 1)

✓ The GAGS score was 21.950± 8.903, positive post acne scar was found in 38.33% of the studied patients and the post inflammatory hyperpigmentation was found in 93.33% (Table 2).

✓ Then mean serum level of OPG in patients group was significantly higher than that in the control group (Table 3)

✓ There was significant correlation between serum OPG levels and the relation to smoking (Graph 1).

✓ There was significant correlation between serum OPG levels and GAGS score while there was negative correlation between serum OPG levels and body mass index (Table 4).

✓ The best cutoff point of osteoprotegerin for the prediction of acne cases was more than 48.4 and the corresponding sensitivity was 95%, specificity was 70%, positive predictive value was 90.5%, negative predictive value was 82.4% and the accuracy was 88.9% (Table 5)

| Table (1): Sociodemographic data of the studied groups |
|-------------------------------------------------------|
| Groups | Patients | Controls | T-Test or Chi-square |
| Age Mean ±SD | 18.833±2.924 | 19.350±3.438 | -0.655 | 0.515 |
| BMI Mean ±SD | 24.637±4.005 | 25.570±4.560 | -0.871 | 0.386 |
| Sex Male | 6 | 10.00 | 4 | 20.00 | 1.371 | 0.242 |
| Female | 54 | 90.00 | 16 | 80.00 |

BMI: body mass index, SD: standard deviation, P<0.05 is significant.
Table (2): Clinical findings in the patients group

| Clinical aspects       | N     | %     |
|------------------------|-------|-------|
| GAGS (Mean± SD)        | 21.95±8.903 |       |
| Positive Post Acne Scar| 23    | 38.33 |
| Positive PIH           | 56    | 93.33 |

GAGs: global acne grading system, SD: standard deviation, PIH: post inflammatory hyperpigmentation.

Table (3): Serum levels of osteoprotegerin in the studied groups

| Groups          | Serum OPG Mean±SD | T-Test | t | P-value |
|-----------------|-------------------|--------|---|---------|
| Patients        | 124.390±75.741    |        | 4.421 | <0.001* |
| Controls        | 47.394±29.332     |        |     |         |

BMI: body mass index, SD: standard deviation, P<0.05 is significant, OPG: osteoprotegerin.

Graph (1): Variation in serum OPG levels between smoking and negative smoking

Table (4): Correlation between serum osteoprotegerin and studied variables

| Correlations   | Serum OPG | R     | P-value |
|----------------|-----------|-------|---------|
| BMI            |           | 0.059 | 0.656   |
| GAGS.          |           | 0.362 | 0.005*  |

BMI: body mass index, OPG: osteoprotegerin, *P<0.05 is significant,

Table (5): Diagnostic performance of osteoprotegerin for acne

| ROC curve between Patients and Controls | Cutoff | Sensitivity % | Specificity % | PPV % | NPV % | Accuracy % |
|----------------------------------------|--------|---------------|--------------|-------|-------|------------|
| Serum OPG                              | >48.4  | 95.00         | 70.00        | 90.5  | 82.4  | 88.9       |

OPG: osteoprotegerin, ROC: receiver operating characteristic, PPV: positive predictive value, NPV: negative predictive value.

Discussion

Acne vulgaris (AV) is the most common cutaneous disorder seen in ambulatory dermatology practice among the pediatric and adult populations\[^{11}\]. Osteoprotegerin (OPG) is a glycoprotein first described in 1997\[^{4}\]. It is produced in many different tissues, including bone, vasculature, heart, lung, kidney, and placenta, and also circulates in plasma, although the concentration here is much lower than in bone and arterial tissue\[^{12}\].

Besides, OPG has other biological functions, including anti-inflammatory actions, such as an anti-apoptotic effect resulting from the binding of TNF-related apoptosis-inducing ligand (TRAIL) with a consequent inhibition of the apoptosis process of susceptible cells. Interestingly, endothelial cells are one of the sites in which the
anti-apoptotic effects of OPG have been demonstrated, suggesting a protective vascular role of the latter. Therefore, OPG has, apart from the aforementioned effects on osteoclastogenesis, other functions in vascular processes and immune responses that may be relevant to the pathogenesis of acne vulgaris. The aim of this study was to evaluate the serum levels of osteoprotegerin in acne vulgaris and assess its relation to the severity of the disease. In this study, the mean age of case was 18.833±2.924 versus 19.350±3.438 in control group. Also, the mean value of BMI was 24.637±4.005 and 25.570±4.560 in case and control group respectively. The majority of cases and control was female (90% & 80% respectively). With insignificant difference between patients and controls regarding age, BMI and sex (p= 0.515, 0.386 and 0.242 respectively). These data coincide with the findings that AV is a common disease occurring throughout the adolescence as in this period the puberty associated with hormonal changes. In particular, androgens increase and cause sebaceous glands in the skin to enlarge and produce more sebum leading to acne lesions. This comes in accordance with the conclusion of acne review which reported that nearly 90% of teenagers in have acne. Rizvi and Chaudry reported that sufficient evidence for a positive relationship between acne and age. This becomes more frequently occurring disease after the time of puberty. In accordance with this study, El-Tonsy et al., 2018 showed the mean of their patients’ age was (23.36 ± 4.84 years.), there were 67 females and 33 males with female predominance (67%) with no significant difference between the genders (P = 0.20). Moreover, females are more affected (45.7%) than the males (29.6%) which was also reported by Tallab, 2004. It might be due to hormonal changes, which are supposed to facilitate the initiation of premenstrual acne. Also, the 1,002 peoples enrolled in Zahra Ghodsi et al. study were 499 boys (49.8%) and 503 girls (50.2%) aged between 12 and 20 years (mean±SD 16±0.9 years). Another study by Ismail and Mohammed-Al (18) who found the same in his study on included 510 patients (173 males and 337 females) with a male: female ratio of 0.41:1. In contrast, a study by Tan and Bhat reported that male patients were more frequently affected, particularly with more severe forms of acne. In current study, 55% of patients had positive family history, 66% had positive relation to stress and 93.33% had positive relation to sun exposure and 86.67% with positive relation to diet. 13.33% only had positive relation to smoking. This observation was explained by a genetic component with increasing rates of acne among twins and first-degree relatives. Also, stress is a cause of increased androgen secretion, increased sebum production, and reducing the immune status. This was in agreement with Bagatin et al., 2014 who found about 50% of his patients reported family history for acne in mother or father but it was of no statistical significant association regarding family history. Regarding sun exposure, there is also a report of Europeans developing a type of acne after a beach holiday (acne Mallorca). A similar phenomenon has been observed in India and is locally referred to as ‘Goa acne’. Regarding dietary habit, it was established from the data that consumption of high glycemic index diet and high glycemic load exacerbates risk of acne occurrence according to Dikshit et al. Also, Qidwai et al. reported that, diets with a high glycemic index, such as white bread, sugar, popcorn, and white rice, are promptly absorbed, conducting increased blood glucose levels. It has been shown to enhance sebum production, stimulate adrenal androgen synthesis, and increase androgen bioavailability and facilitating cell proliferation, all of which play a role in the pathogenesis of acne. Bowe et al. reported that the occurrence of acne is lower in rural and non-industrialized areas than
in Western populations. It is believed that it may be a result of differences between glycemic loads of diets of both populations. Alanazi et al.\(^{(25)}\) found post inflammatory hyperpigmentation and scarring were present in 11.6\% and 8.7\% respectively, and scar was absent in most of cases (91.3\%). However, El-Hamd et al.\(^{(26)}\) found that 75\% had post acne scarring, but this difference might be explained by the fact that our study is a community based study and the latter study is a hospital based study. This study was the first trial was conducted to explore the role of OPG in pathogenesis of acne. Our idea was based on its relationship with obesity and insulin resistance which explored in many trials. As the insulin resistance and hyperglycemia, fat & sugar rich food were implicated in pathogenesis of acne. Also, the role of OPG in PCO (acne was one of clinical symptoms in it) was cleared in recent trials. A published data by Holecki et al.\(^{(27)}\) showed that obesity and insulin resistance result in a decrease in serum OPG concentrations. Also, Yin et al.\(^{(28)}\) revealed the adipose tissue, predominantly visceral adipose tissue (VAT), produces and secretes a variety of bioactive adipocytokines. However, VAT accumulation induces adipocytes dysfunction, including oversecretion of interleukin-6, tumor necrosis factor-\(\alpha\), plasminogen activator inhibitor-1 and visfatin, and hyposecretion of adiponectin, which were supposed to be involved in the pathogenesis of insulin resistance and abnormal glucose metabolism. Also, Avington et al.\(^{(29)}\) reported that increased circulating OPG levels have also found in association with the presence and severity of coronary artery disease, peripheral artery disease and stroke, suggesting that OPG may serve as a biomarker of established atherosclerosis in humans. A study by Genc et al.\(^{(30)}\) included 40 healthy volunteers and 40 psoriasis patients. The mean serum osteoprotegerin level was 279.3 ± 24.8 pg/ml in the psoriasis group and 273.9 ± 26.3 pg/ml in the healthy control group (\(p > 0.05\)). Also, Lappin et al., 2007\(^{(31)}\) support our finding, as they reported that, cigarette smoker patients tended to have lower serum concentrations of OPG than non-smoker patients, there were significant differences in the median serum concentration of OPG (smokers 23.76 pM, non-smokers 59.28 pM) and the ratio of serum concentrations of OPG. Concentrations of OPG in the smoker patients also had a statistically significant negative correlation with tobacco consumption.

**Conclusion**

The difference of osteoprotegerin levels was significantly differentiated between the patients with acne and the healthy control group. OPG may play a role in acne vulgaris pathogenesis.

**References**

1. Bhate K and Williams HC (2013): Epidemiology of acne vulgaris. Br J Dermatol.; 168: 474-485.
2. Dawson AL, Dellavalle RP (2013): Acne vulgaris. BMJ., 346: f2634.
3. Abulnaja KO (2009): Changes in the hormone and lipid profile of obese adolescent Saudi females with acne vulgaris. Braz J Med Biol Res.; 42: 501-50.
4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997): "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density". Cell. 89 (2): 309–19.
5. Krakauer T (2008). Nuclear factor-kappaB: fine-tuning a central integrator of
diverse biologic stimuli. International Reviews of Immunology. 27 (5): 286–92.

6. Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, Pascual V, Hood LE and Clark EA (1998): OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol.; 6113–6121.

7. Brandstrom H, Bjorkmann T and Ljunggren O (2001): Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun.; 280: 831–835.

8. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, et al (2006): Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 12(12): 1372–9.

9. Sangwan D (2016): A study of body mass index between private and government school children. Int J Phys Educ Sports Health; 3 (1): 63-65.

10. Doshi A, Zaheer A and Stiller MJ (1997): A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol; 36(6): 416-8.

11. Davis SA, Narahari S, Feldman SR, et al. (2012): Top dermatologic conditions in patients of color: an analysis of nationally representative data. Journal of drugs in dermatology: JDD 11: 466–473.

12. Nybo M and Rasmussen LM. (2008): The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. European Journal of Endocrinology 159: 603-608.

13. Escobar-Morreale HF, Botella-Carretero JI, Martínez-García MÁ, et al. (2008): Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. European Journal of Endocrinology 159: 225-232.

14. Rizvi F and Chaudry MA. (2009): Precipitating factors of acne vulgaris in females. Ann. Pak. Inst. Med. Sci 5: 104-107.

15. El-Tonsy TMK, Mohammed MA, Hamed E-E, et al. (2018): Bacteriological study of Acne Vulgaris in Cairo Egypt. Egyptian Journal of Hospital Medicine 72.

16. Tallab TM. (2004): Beliefs, perceptions and psychological impact of acne vulgaris among patients in the Assir region of Saudi Arabia. West African journal of medicine 23: 85-87.

17. Zahra Ghodsi S, Orawa H and Zouboulis CC. (2009): Prevalence, Severity, and Severity Risk Factors of Acne in High School Pupils: A Community-Based Study. Journal of Investigative Dermatology 129: 2136-2141.

18. Ismail KH and Mohammed-Ali KB. (2012): Quality of life in patients with acne in Erbil city. Health and quality of life outcomes 10: 60.

19. Tan J and Bhatke K. (2015b): A global perspective on the epidemiology of acne. British Journal of Dermatology 172: 3-12.

20. Bagatin E, Timpano DL, Guadanhim LRdS, et al. (2014): Acne vulgaris: prevalence and clinical forms in adolescents from São Paulo, Brazil. Anais brasileiros de dermatologia 89: 428-435.

21. Tan J and Bhatke K. (2015a): A global perspective on the epidemiology of acne. British Journal of Dermatology 172: 3-12.

22. Dikshit A, Qidwai A, Pandey M, et al. (2017): Risk factor assessment for acne vulgaris in human and implications for public health interventions in north central India: A survey based study.

23. QIDWAI A, PANDEY M, SHUKLA SK, et al. (2017): Risk factor assessment for acne vulgaris in human and implications for public health interventions.
in North Central India: a survey-based study. RISK 10.

24. **Bowe WP, Joshi SS and Shalita AR. (2010):** Diet and acne. Journal of the American Academy of Dermatology 63: 124-141.

25. **Alanazi MS, Hammad SM and Mohamed AE. (2018):** Prevalence and psychological impact of Acne vulgaris among female secondary school students in Arar city, Saudi Arabia, in 2018. Electron Physician 10: 7224-7229.

26. **El-Hamd MA, Nada EEDAA, Moustafa MAK, et al. (2017):** Prevalence of acne vulgaris and its impact of the quality of life among secondary school-aged adolescents in Sohag Province, Upper Egypt. Journal of cosmetic dermatology 16: 370-373.

27. **Holecki M, Zahorska- Markiewicz B, Janowska J, et al. (2007):** The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women. Obesity 15: 1925-1929.

28. **Yin Y, Hou X-h, Pan X-p, et al. (2009):** Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes. Chinese medical journal 122: 2530-2533.

29. **Avignon A, Sultan A, Piot C, et al. (2007):** Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 30: 2934-2939.

30. **Genc M, Can M, Guven B, et al. (2017):** Evaluation of Serum Fetuin-A and Osteoprotegerin Levels in Patients with Psoriasis. Indian Journal of Clinical Biochemistry 32: 90-94.

31. **Lappin DF, Sherrabeh S, Jenkins WMM, et al. (2007):** Effect of smoking on serum RANKL and OPG in sex, age and clinically matched supportive-therapy periodontitis patients. Journal of Clinical Periodontology 34: 271-277.